Leukemia, Myeloid, Acute

"Leukemia, Myeloid, Acute" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Descriptor ID	D015470
MeSH Number(s)	C04.557.337.539.275
Concept/Terms	Leukemia, Myeloid, Acute Leukemia, Myeloid, Acute Acute Myeloid Leukemia Acute Myeloid Leukemias Leukemias, Acute Myeloid Myeloid Leukemias, Acute ANLL Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Myeloblastic, Acute Leukemia, Myelocytic, Acute Leukemia, Myelogenous, Acute Leukemia, Nonlymphoblastic, Acute Leukemia, Nonlymphocytic, Acute Myeloblastic Leukemia, Acute Acute Myeloblastic Leukemia Acute Myeloblastic Leukemias Leukemia, Acute Myeloblastic Leukemias, Acute Myeloblastic Myeloblastic Leukemias, Acute Myelocytic Leukemia, Acute Acute Myelocytic Leukemia Acute Myelocytic Leukemias Leukemia, Acute Myelocytic Leukemias, Acute Myelocytic Myelocytic Leukemias, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Nonlymphoblastic Leukemia, Acute Acute Nonlymphoblastic Leukemia Acute Nonlymphoblastic Leukemias Leukemia, Acute Nonlymphoblastic Leukemias, Acute Nonlymphoblastic Nonlymphoblastic Leukemias, Acute Nonlymphocytic Leukemia, Acute Acute Nonlymphocytic Leukemia Acute Nonlymphocytic Leukemias Leukemia, Acute Nonlymphocytic Leukemias, Acute Nonlymphocytic Nonlymphocytic Leukemias, Acute Acute Myelogenous Leukemia Acute Myelogenous Leukemias Leukemias, Acute Myelogenous Myelogenous Leukemias, Acute Myeloid Leukemia, Acute, M1 Myeloid Leukemia, Acute, M1 Leukemia, Myeloid, Acute, M1 Acute Myeloid Leukemia without Maturation Leukemia, Myeloid, Acute, M2 Leukemia, Myeloid, Acute, M2 Myeloid Leukemia, Acute, M2 Acute Myeloid Leukemia with Maturation

Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Acute".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Leukemia [C04.557.337]
Leukemia, Myeloid [C04.557.337.539]
Leukemia, Myeloid, Acute [C04.557.337.539.275]

Below are MeSH descriptors whose meaning is related to "Leukemia, Myeloid, Acute".

Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Acute".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Leukemia, Myeloid, Acute" by people in this website by year, and whether "Leukemia, Myeloid, Acute" was a major or minor topic of these publications.

Bar chart showing 79 publications over 25 distinct years, with a maximum of 8 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1998	2	0	2
2000	1	0	1
2002	1	0	1
2003	2	0	2
2004	2	0	2
2005	1	0	1
2008	1	2	3
2009	2	1	3
2010	3	0	3
2011	4	0	4
2012	2	0	2
2013	3	2	5
2014	4	0	4
2015	3	2	5
2016	2	0	2
2017	5	0	5
2018	3	1	4
2019	5	0	5
2020	2	0	2
2021	8	0	8
2022	6	0	6
2023	2	0	2
2024	4	0	4
2025	2	0	2

Below are the most recent publications written about "Leukemia, Myeloid, Acute" by people in Profiles.

Gooptu M, Murdock HM, Soiffer RJ. How I treat AML relapse after allogeneic HSCT. Blood. 2025 May 08; 145(19):2128-2137.

View in: PubMed
Gyan E, Minden MD, Kubo K, Rambaldi A, Juliusson G, J?dersten M, Kelly RJ, Szerafin L, He W, Gill SC, Hill JE, Chen C, Delgado D, Hasabou N. Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study. Cancer. 2025 Feb 15; 131(4):e35746.

View in: PubMed
Hlavaty SI, Salcido KN, Pniewski KA, Mukha D, Ma W, Kannan T, Cassel J, Srikanth YVV, Liu Q, Kossenkov A, Salvino JM, Chen Q, Schug ZT. ACSS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis. Cell Rep. 2024 12 24; 43(12):114988.

View in: PubMed
Kim HT, Ho VT, Nikiforow S, Cutler C, Koreth J, Shapiro RM, Gooptu M, Romee R, Wu CJ, Antin JH, Ritz J, Soiffer RJ. Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis. Transplant Cell Ther. 2024 07; 30(7):687.e1-687.e13.

View in: PubMed
Wysota M, Konopleva M, Mitchell S. Novel Therapeutic Targets in Acute Myeloid Leukemia (AML). Curr Oncol Rep. 2024 04; 26(4):409-420.

View in: PubMed
Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J, Cutler CS, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro R, DeAngelo DJ, Stone RM, Bat-Erdene D, Ryan J, Contreras ME, Fell G, Letai A, Ritz J, Lindsley RC, Soiffer RJ, Antin JH. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024 02 27; 8(4):978-990.

View in: PubMed
Knorr K, Rahman J, Erickson C, Wang E, Monetti M, Li Z, Ortiz-Pacheco J, Jones A, Lu SX, Stanley RF, Baez M, Fox N, Castro C, Marino AE, Jiang C, Penson A, Hogg SJ, Mi X, Nakajima H, Kunimoto H, Nishimura K, Inoue D, Greenbaum B, Knorr D, Ravetch J, Abdel-Wahab O. Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nat Cancer. 2023 12; 4(12):1675-1692.

View in: PubMed
Vergara-Cadavid J, Johnson PC, Kim HT, Yi A, Sise ME, Leaf DE, Hanna PE, Ho VT, Cutler CS, Antin JH, Gooptu M, Kelkar AH, Wells SL, Nikiforow S, Koreth J, Romee R, Soiffer RJ, Shapiro RM, Gupta S. Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023 07; 29(7):455.e1-455.e9.

View in: PubMed
Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, Deeg HJ, Sallman D, Gallacher P, Wennborg A, Hickman DK, Attar EC, Fernandez HF. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2022 12 01; 40(34):3985-3993.

View in: PubMed
Ho VT, Kim HT, Brock J, Galinsky I, Daley H, Reynolds C, Weber A, Pozdnyakova O, Severgnini M, Nikiforow S, Cutler C, Koreth J, Alyea EP, Antin JH, Gooptu M, Romee R, Shapiro R, Chen YB, Rosenblatt J, Avigan D, Hodi FS, Dranoff G, Wu CJ, Ritz J, Soiffer RJ. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Adv. 2022 04 12; 6(7):2183-2194.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement